Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2019 16:10 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review

CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
May 01, 2019 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
April 08, 2019 08:30 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases

CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
March 29, 2019 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis

CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
March 19, 2019 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Announces Appointment of Cynthia Smith to its Board of Directors

CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
March 01, 2019 08:30 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics to Present at March Investor Conferences

CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
February 26, 2019 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720

CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
February 04, 2019 07:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
January 29, 2019 08:00 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial

CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
January 07, 2019 16:01 ET | Source: Spero Therapeutics, Inc.

Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...

Next Page keyboard_arrow_right